CCDC12

Across TCGA pan-cancer cohorts, CCDC12 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CCDC12 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CCDC12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC12 expression acts as an unfavorable survival marker.

HNSC, BLCA, and COAD are the cancer types where CCDC12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.146	0.768	<.001	24	view →
BLCA	DFS	Median	All	0.247	0.627	.039	12	view →
COAD	OS	Median	All	0.001	0.871	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CCDC12–HNSC (OS)

Open the HNSC breakdown →